(News Bulletin 247) – AstraZeneca announces that it has updated and simplified its contractual agreements with Swedish Orphan Biovitrum AB (Sobi) and Sanofi relating to the development and commercialization of nirsevimab in the United States.
‘Given the upcoming launch of nirsevimab in the United States and other markets, the simplification of the prior arrangements clarifies the roles and responsibilities of the parties involved’ indicates the laboratory.
As a result of this simplification agreement, Sanofi will pay royalties to Sobi as sales of nirsevimab in the United States are realized, and the liability related to future obligations will be eliminated.
AstraZeneca will register a gain of $0.7 billion, which will be recognized in other basic operating income in 2023. The agreement will not affect AstraZeneca’s financial forecast for 2023, the laboratory specifies .
As a reminder, nirsevimab – or Beyfortus according to its trade name – is an experimental long-acting antibody aimed at protecting infants against RSV infections, from their birth until their first viral season by means of a single dose.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
